BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their latest report:”AAV-based gene therapy Products: Ongoing Clinical Trials“. This 205-page report provides you with a unique exhaustive overview of 116 ongoing trials for the treatment of 40 diseases (as of June 2020). More than 80 products from 49 companies and academic institutions are described.
Areas covered: Cardiovascular Diseases, Hematological Diseases, Hepatic Diseases, Infectious Diseases, inherited Metabolic Diseases, Lysosomal Diseases, Neurological Diseases, Neuromuscular Diseases and Ophthalmological Diseases
You can click here to get sample pages and click here to get the order form (€590, excl. VAT)
AAV-Based Gene Therapy Products: Ongoing Clinical Trials (June 2020)
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their latest report:”AAV-based gene therapy Products: Ongoing Clinical Trials“. This 205-page report provides you with a unique exhaustive overview of 116 ongoing trials for the treatment of 40 diseases (as of June 2020). More than 80 products from 49 companies and academic institutions are described.
Areas covered: Cardiovascular Diseases, Hematological Diseases, Hepatic Diseases, Infectious Diseases, inherited Metabolic Diseases, Lysosomal Diseases, Neurological Diseases, Neuromuscular Diseases and Ophthalmological Diseases
You can click here to get sample pages and click here to get the order form (€590, excl. VAT)
CONTINUE READING...
- A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies
- AskBio acquires BrainVectis, a French gene therapy company dedicated to neurodegenerative diseases
- Trend Chart on Innovative Bioindustries April 12th
- Trend Chart On Innovative Biotherapies March 28th
COMMENTS ARE OFF THIS POST